Do analysts recommend RNXT or INGN?

RenovoRx currently has a consensus target price of $8.50, indicating a potential upside of 639.13%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts plainly believe RenovoRx is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, RNXT or INGN?

RenovoRx has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 46.26 -$11.17M -$0.33 N/A Inogen $348.67M 0.46 -$22.75M -$0.90 N/A

Is RNXT or INGN more profitable?

Inogen has a net margin of -6.94% compared to RenovoRx's net margin of -823.98%. Inogen's return on equity of -13.17% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% Inogen -6.94% -13.17% -8.36%

Does the media refer more to RNXT or INGN?

In the previous week, Inogen had 6 more articles in the media than RenovoRx. MarketBeat recorded 9 mentions for Inogen and 3 mentions for RenovoRx. Inogen's average media sentiment score of 0.28 beat RenovoRx's score of 0.00 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APYX or RNXT more profitable?

Apyx Medical has a net margin of -14.78% compared to RenovoRx's net margin of -823.98%. Apyx Medical's return on equity of -76.60% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% RenovoRx -823.98% -135.03% -101.92%

Does the media favor APYX or RNXT?

In the previous week, Apyx Medical had 18 more articles in the media than RenovoRx. MarketBeat recorded 21 mentions for Apyx Medical and 3 mentions for RenovoRx. Apyx Medical's average media sentiment score of 0.58 beat RenovoRx's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apyx Medical 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, RNXT or OWLT?

RenovoRx has higher earnings, but lower revenue than Owlet. RenovoRx is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 46.26 -$11.17M -$0.33 N/A Owlet $105.70M 1.50 -$39.68M -$3.07 N/A

Is RNXT or OWLT more profitable?

Owlet has a net margin of -42.54% compared to RenovoRx's net margin of -823.98%. Owlet's return on equity of 0.00% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% Owlet -42.54% N/A -18.02%

Does the media prefer RNXT or OWLT?

In the previous week, RenovoRx and RenovoRx both had 3 articles in the media. RenovoRx's average media sentiment score of 0.00 equaled Owlet'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Owlet 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RNXT or STIM more profitable?

Neuronetics has a net margin of -24.48% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% Neuronetics -24.48% -139.83% -27.13%

Does the media refer more to RNXT or STIM?

In the previous week, Neuronetics had 9 more articles in the media than RenovoRx. MarketBeat recorded 12 mentions for Neuronetics and 3 mentions for RenovoRx. Neuronetics' average media sentiment score of 0.05 beat RenovoRx's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, RNXT or CVRX?

RenovoRx has higher earnings, but lower revenue than CVRx. RenovoRx is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 46.26 -$11.17M -$0.33 N/A CVRx $56.65M 1.22 -$53.31M -$1.98 N/A

Is RNXT or CVRX more profitable?

CVRx has a net margin of -84.93% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% CVRx -84.93% -152.35% -50.93%

Does the media refer more to RNXT or CVRX?

In the previous week, CVRx had 20 more articles in the media than RenovoRx. MarketBeat recorded 23 mentions for CVRx and 3 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat CVRx's score of -0.46 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 1 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

RenovoRx (RNXT) Competitors

$1.15 -0.01 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.15 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

RNXT vs. INGN, APYX, OWLT, STIM, and CVRX

Should you buy RenovoRx stock or one of its competitors? RenovoRx's main competitors and comparable companies include Inogen (INGN), Apyx Medical (APYX), Owlet (OWLT), Neuronetics (STIM), and CVRx (CVRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does RenovoRx compare to Inogen?

RenovoRx (NASDAQ:RNXT) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

RenovoRx currently has a consensus target price of $8.50, indicating a potential upside of 639.13%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts plainly believe RenovoRx is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Inogen had 6 more articles in the media than RenovoRx. MarketBeat recorded 9 mentions for Inogen and 3 mentions for RenovoRx. Inogen's average media sentiment score of 0.28 beat RenovoRx's score of 0.00 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

RenovoRx has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	46.26	-$11.17M	-$0.33	N/A
Inogen	$348.67M	0.46	-$22.75M	-$0.90	N/A

RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Inogen has a net margin of -6.94% compared to RenovoRx's net margin of -823.98%. Inogen's return on equity of -13.17% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Inogen	-6.94%	-13.17%	-8.36%

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

RenovoRx and Inogen tied by winning 8 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 15.9% of Apyx Medical shares are owned by company insiders. Comparatively, 9.4% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apyx Medical currently has a consensus target price of $6.60, indicating a potential upside of 118.54%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 639.13%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Apyx Medical has a net margin of -14.78% compared to RenovoRx's net margin of -823.98%. Apyx Medical's return on equity of -76.60% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
RenovoRx	-823.98%	-135.03%	-101.92%

Apyx Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

In the previous week, Apyx Medical had 18 more articles in the media than RenovoRx. MarketBeat recorded 21 mentions for Apyx Medical and 3 mentions for RenovoRx. Apyx Medical's average media sentiment score of 0.58 beat RenovoRx's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apyx Medical	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RenovoRx has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.41	-$11.21M	-$0.20	N/A
RenovoRx	$1.12M	46.26	-$11.17M	-$0.33	N/A

Summary

Apyx Medical beats RenovoRx on 11 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Owlet?

RenovoRx (NASDAQ:RNXT) and Owlet (NYSE:OWLT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 72.6% of Owlet shares are held by institutional investors. 9.4% of RenovoRx shares are held by company insiders. Comparatively, 36.2% of Owlet shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

RenovoRx currently has a consensus price target of $8.50, suggesting a potential upside of 639.13%. Owlet has a consensus price target of $15.00, suggesting a potential upside of 174.78%. Given RenovoRx's stronger consensus rating and higher probable upside, research analysts clearly believe RenovoRx is more favorable than Owlet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Owlet has a net margin of -42.54% compared to RenovoRx's net margin of -823.98%. Owlet's return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Owlet	-42.54%	N/A	-18.02%

In the previous week, RenovoRx and RenovoRx both had 3 articles in the media. RenovoRx's average media sentiment score of 0.00 equaled Owlet'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Owlet	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Owlet has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

RenovoRx has higher earnings, but lower revenue than Owlet. RenovoRx is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	46.26	-$11.17M	-$0.33	N/A
Owlet	$105.70M	1.50	-$39.68M	-$3.07	N/A

Summary

Owlet beats RenovoRx on 9 of the 15 factors compared between the two stocks.

How does RenovoRx compare to Neuronetics?

RenovoRx (NASDAQ:RNXT) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

RenovoRx has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	46.26	-$11.17M	-$0.33	N/A
Neuronetics	$149.16M	1.49	-$39M	-$0.54	N/A

RenovoRx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

RenovoRx presently has a consensus price target of $8.50, indicating a potential upside of 639.13%. Neuronetics has a consensus price target of $4.50, indicating a potential upside of 41.07%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 9.4% of RenovoRx shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neuronetics has a net margin of -24.48% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Neuronetics	-24.48%	-139.83%	-27.13%

In the previous week, Neuronetics had 9 more articles in the media than RenovoRx. MarketBeat recorded 12 mentions for Neuronetics and 3 mentions for RenovoRx. Neuronetics' average media sentiment score of 0.05 beat RenovoRx's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

RenovoRx beats Neuronetics on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to CVRx?

RenovoRx (NASDAQ:RNXT) and CVRx (NASDAQ:CVRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

RenovoRx currently has a consensus price target of $8.50, suggesting a potential upside of 639.13%. CVRx has a consensus price target of $6.90, suggesting a potential upside of 165.38%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts plainly believe RenovoRx is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CVRx	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, CVRx had 20 more articles in the media than RenovoRx. MarketBeat recorded 23 mentions for CVRx and 3 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat CVRx's score of -0.46 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CVRx	1 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

CVRx has a net margin of -84.93% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
CVRx	-84.93%	-152.35%	-50.93%

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, CVRx has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 16.6% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

RenovoRx has higher earnings, but lower revenue than CVRx. RenovoRx is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	46.26	-$11.17M	-$0.33	N/A
CVRx	$56.65M	1.22	-$53.31M	-$1.98	N/A

Summary

RenovoRx beats CVRx on 9 of the 16 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.81M	$5.73B	$6.99B	$12.83B
Dividend Yield	N/A	1.78%	2.58%	10.06%
P/E Ratio	-3.48	25.00	268.64	24.76
Price / Sales	46.26	40.03	585.26	96.30
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	7.67	6.19	11.31	6.45
Net Income	-$11.17M	$147.25M	$3.44B	$347.05M
7 Day Performance	10.58%	1.89%	2.25%	0.98%
1 Month Performance	23.64%	2.44%	-0.25%	-0.64%
1 Year Performance	3.14%	9.91%	76.14%	22.27%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	3.6272 of 5 stars	$1.15 -0.9%	$8.50 +639.1%	+1.8%	$51.81M	$1.12M	N/A	6	News Coverage Upcoming Earnings
INGN Inogen	1.2612 of 5 stars	$6.92 +3.1%	N/A	-7.1%	$181.67M	$348.67M	N/A	1,030	News Coverage Earnings Report
APYX Apyx Medical	3.0698 of 5 stars	$4.28 +2.4%	$6.60 +54.2%	+58.7%	$175.19M	$52.84M	N/A	270	Trending News Earnings Report Analyst Revision
OWLT Owlet	2.3058 of 5 stars	$5.33 -1.9%	$15.00 +181.6%	-41.8%	$157.82M	$105.70M	N/A	106	News Coverage Earnings Report
STIM Neuronetics	3.4439 of 5 stars	$2.30 +6.5%	$4.00 +73.9%	-47.5%	$150.31M	$149.16M	N/A	180	Trending News Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors